A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Patients who participated in the core EPO2121 study and did not clinically progress may participate in this extension protocol to further evaluate the safety, tolerability, and efficacy of patupilone.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Epothilone B; Epothilones

Criteria

Inclusion Criteria:

• Completion of the core study is required for participation in the extension.

• 18 years of age or older

• World Health Organization (WHO) Performance Status score of: 0 - you are fully active and more or less as you were before your illness; 1 - you cannot carry out heavy physical work, but can do anything else; or 2 - you are up and about more than half the day, you can look after yourself, but are not well enough to work.

• Life expectancy of 3 months or more

• Patients with measurable or evaluable disease who have histologically documented advanced solid tumor and who have progressed after systemic therapy or for whom standard systemic therapy does not exist

Exclusion Criteria:

• Severe and/or uncontrolled medical disease

• Known diagnosis of human immunodeficiency virus (HIV) infection

• Presence of any other active or suspected acute or chronic uncontrolled infection

• Severe cardiac insufficiency, with uncontrolled and/or unstable cardiac or coronary artery disease

• History of another malignancy within 5 years prior to study entry, except for curatively treated non-melanotic skin cancer or cervical cancer in situ

Other protocol-defined inclusion/exclusion criteria may apply.